Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-12-20
2005-12-20
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S255060, C514S275000, C544S322000, C544S331000, C544S405000
Reexamination Certificate
active
06977259
ABSTRACT:
A compound of formula (I)or a salt, ester, amide or prodrug thereof; R5is an optionally substituted 6-membered aromatic ring containing at least one nitrogen atom, and R1, R2, R3, R4are independently selected from halogeno, cyano, nitro, C1-3alkylsulphonyl, —N(OH)R7— (wherein R7is hydrogen, or C1-3alkyl), or R9X1— (wherein X1represents a direct bond, —O—, —CH2—, —OC(O)—, —C(O)—, —S—, —SO—, —SO2—, —NR10C(O)—, —C(O)NR11—, —SO2NR12—, —NR13SO2— or —NR14— (wherein R10, R11, R12, R13and R14each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl), and R9is hydrogen, optionally substituted hydrocarbyl, optionally substituted heterocyclyl or optionally substituted alkoxy); provided that at least one of R2or R3is other than hydrogen. These compounds are inhibitors of aurora 2 kinase. Thus they, and pharmaceutical compositions containing them, are useful in methods of treatment of proliferative disease such as cancer and in particular cancers such as colorectal or breast cancer where aurora 2 is upregulated.
REFERENCES:
patent: 3075981 (1963-01-01), Surrey
patent: 0 860 433 (1998-08-01), None
patent: 2.154.326 (1973-05-01), None
patent: WO 92/20642 (1992-11-01), None
patent: WO 96/09294 (1996-03-01), None
patent: WO 99/35132 (1999-07-01), None
patent: WO 99/35146 (1999-07-01), None
patent: WO 01/40218 (2001-06-01), None
Hawley's Condensed Chemical Dictionary, 13thed., pp. 825 and 837 © 1997 by Van Nostrand Reinhold.
Ganapathi et al., Chem Abstract 47:22276.
Abdel-Halim et al., Chem. Abstract 121:35528.
Ishikawa et al., Chem. Abstract 121: 134158.
Abdel-Halim, A.M. et al. Synthesis and biological activity of some 4-(p-chlorophenyl)-6-(o-hydroxyphenyl)-2-aminopyrimidine derivatives: Part 1. Chemical Abstracts 121, 1011 (Abstract No. 121: 35528) (Jul. 18, 1994).
Gargallo, J.C. 4-(2-Pyridylamino)-7-chloroquinoline. Chemical Abstracts 61, 14646 (Dec. 1, 1964).
Ishikawa, K. et al. Preparation of 3-[(2-pyrimidinyl and 2-triazinyl)amino] quinoline derivatives as agrochemical fungicides. Chemical Abstracts 121, 1040 (Abstract No. 134158) (Sep. 12, 1994).
Kubo, K. et al. A Novel Series of 4-Phenoxyquinolines: Potent and Highly Selective Inhibitors of PDGF Receptor Autophosphorylation. Bioorganic & Medicinal Chem. Letts. 7, 2935-2940 (1997).
Jung Frederic Henri
Mortlock Andrew Austen
AstraZeneca AB
Tucker Zachary C.
Wilson James O.
LandOfFree
Quinoline derivatives and their use as aurora 2 kinase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinoline derivatives and their use as aurora 2 kinase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinoline derivatives and their use as aurora 2 kinase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3487581